- Conditions
- Secondary Hypogonadism
- Interventions
- Placebo, topical testosterone, Androxal
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 21 Years to 65 Years · Male only
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 18
- States / cities
- Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 4,634
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Pharmacokinetic Study, Ulixertinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- OC-Go
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 8 participants
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- COVID-19
- Interventions
- Remdesivir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Madera, California + 17 more
- Conditions
- Rift Valley Fever
- Interventions
- IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3, IDB-011 dose level 4, IDB-011 dose level 5, Placebo
- Drug · Other
- Lead sponsor
- IDBiologics, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Interventions
- AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.
- Drug
- Lead sponsor
- Advenchen Laboratories, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Venetoclax, Azacitidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Fountain Valley, California • Los Angeles, California + 21 more
- Conditions
- Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects
- Interventions
- Melody Transcatheter Pulmonary Valve PB1016
- Device
- Lead sponsor
- Medtronic Heart Valves
- Industry
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Detroit, Michigan • Columbus, Ohio + 2 more
- Conditions
- Friedreich's Ataxia
- Interventions
- Vatiquinone
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
- Conditions
- Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Interventions
- Eribulin mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more
- Conditions
- Hypogonadism
- Interventions
- Testosterone undecanoate, Testosterone enanthate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Antonio, Texas
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- rAd-IFN, Celecoxib Oral Product, Gemcitabine
- Biological · Drug
- Lead sponsor
- Ferring Ventures Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Ipilimumab, Nivolumab, Paclitaxel, Positron Emission Tomography, Radiation Therapy
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 488
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more
- Conditions
- Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Partial Hydatidiform Mole
- Interventions
- Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Other · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 28
- States / cities
- Mountain View, California • Palo Alto, California • San Francisco, California + 21 more
- Conditions
- Language Impairment, Down Syndrome
- Interventions
- Jasper-EMT with words and AAC
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 30 Months to 54 Months
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Nashville, Tennessee
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 52
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
- Conditions
- Anxiety, Depression
- Interventions
- Alpha-Stim Active, Alpha-Stim Inactive
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Degenerative Joint Disease
- Interventions
- Group A (corticosteroid injection group), Group B (platelet rich plasma injection group)
- Drug · Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dry Macular Degeneration
- Interventions
- SS-OCT imaging
- Device
- Lead sponsor
- Boston Image Reading Center
- Industry
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 46
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more
- Conditions
- Chronic Abdominal Pain, Small Intestinal Bacterial Overgrowth
- Interventions
- Lactulose Breath Test, xifaxan, placebo
- Procedure · Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- IW-1973, Placebo
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more
- Conditions
- Heart Failure
- Interventions
- Torsemide, Furosemide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,973 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 60
- States / cities
- Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
- Conditions
- Quadriplegia
- Interventions
- Neural Communication System
- Device
- Lead sponsor
- Richard A. Andersen, PhD
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2031
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Pasadena, California • Pomona, California